Healthcare Industry News:  Merck 

Diagnostics Oncology Personnel

 News Release - October 6, 2014

bioTheranostics Appoints Nicolas Barthelemy as President and CEO

Industry Veteran to Lead Organization as It Expands Commercialization of Its Molecular Diagnostic Tests for Breast and Metastatic Cancers

SAN DIEGO--(Healthcare Sales & Marketing Network)--bioTheranostics, Inc., a leader in molecular diagnostics for cancer, has appointed life sciences industry veteran Nicolas Barthelemy to the position of president and CEO. Barthelemy succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.

“We are very excited to have Nicolas come on board and lead the company in its next phase of commercial expansion,” Ding said. “He has a proven ability and track record to build high-performance teams that are able to achieve rapid and sustained improvements in business results. It is our belief that under Nicolas’ leadership, bioTheranostics will continue its significant progress in advancing the personalized care of cancer patients.”

Barthelemy brings extensive global leadership experience and a track record of success in the life sciences and biopharmaceutical industries. Prior to joining bioTheranostics, he held a number of executive-level positions at Life Technologies/Invitrogen, including Chief Commercial Officer and President of the Cell Systems Division. He also held senior-level positions at Biogen Idec, and he began his career at Merck & Co. He currently serves on the Boards of several private and public life sciences companies. Barthelemy earned a Master of Science in chemical engineering from the University of California, Berkeley, and a graduate degree in chemistry from the Ecole Supérieure de Physique et Chimie Industrielles in Paris.

“bioTheranostics has played a very important role in the remarkable progress that is being made in molecular diagnostics,” Barthelemy said. “Building on decade-long pioneering work involving the discovery, clinical development, and validation of novel biomarkers, the company is now on a trajectory to become a recognized leader in the field of next-generation cancer diagnostics. More importantly, it also is in a unique position to make a profound and positive difference in cancer care and in the quality of life of cancer patients and their families. The combination of best-in-class molecular tests addressing high unmet needs with the outstanding team built by Richard provides a solid foundation on which to take the company to the next level, and I very much look forward to the journey.”

About bioTheranostics

bioTheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its bioT3 Metastatic Cancer Solution combines accurate diagnosis with comprehensive biomarker information that allows improved treatment for metastatic cancer patients. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.


Source: bioTheranostics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.